CDGSF, a novel STING agonist that induces a “hot” tumor microenvironment to inhibit melanoma progression, has been shown to induce a robust adaptive immune response as an adjuvant to SARS-CoV-2 stinger protein and has great potential to be an adjuvant for cancer vaccines (97). This evidence concerns the gene STING1 and cancer.